Articles On Micro-X (ASX:MX1)

  Ansell is expanding its manufacturing to be less reliant on China Mayne Pharma pre-announces a strong first-half earnings recovery Alterity Therapeutics raises $40 million on the back of encouraging trial   The maker of personal protect...

  Percheron has detailed why its Duchenne muscular dystrophy trial flopped – and why it needs to find a new drug candidate Imugene’s multiple oncology and inflammation programs aren’t helping its valuation Impedimed and Micro-X raise funds...

  Emyria says its ‘real world’ MDMA trial shows a “sustained improvement” in post-traumatic stress disorder (PTSD) symptoms Argenica says its traumatic brain injury candidate works in rats – and ferrets The biotech sector advanced to recor...

The Nasdaq hit all-time highs in January but DeepSeek is shaking up the AI market ASX tech stocks shows resilience despite global sell-off Pointerra, Hydrix among the best tech stocks last month   The first month of 2025 was one to rememb...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

The S&P/ASX 200 fell 3% in December as Santa rally failed to eventuate yet again  Consumer staples led the S&P/ASX 200 sectors in December with tech leading overall in 2024 Niobium and rare earths explorer Aldoro Resources led the...

ASX tech sector up 50pc in 2024, Nasdaq climbs 25pc Archer Materials best tech stock in December Dubber and Brainchip also winners after scoring big contracts   While everyone’s busy drooling over the US mega-tech stocks, there’s a quiet...

It’s been tough going for the ASX on Friday ahead of key US jobs report Bitcoin cooled off after record highs as profit-taking hit APA was up on pipeline news; Iluka slumped on cost blowout   After hitting fresh record highs earlier this...

The ASX200 closed down 0.38% at 8,462 points. Oil steadied after the biggest advance in more than two weeks as OPEC+ made progress towards a deal to delay further the restoration of shuttered supply, and the U.S. imposed more sanctions o...

Aussie shares rebound slightly after GDP data RBA rate cut talk grows amid weak growth Rio Tinto and Sumitomo ink $615m copper deal   Aussie shares were down by about 0.4% on Wednesday, after falling as much as 0.8% earlier in the day. Th...

AI boom lifts ASX tech stocks, XIJ index up 10% in November Appen and Life360 have surged this year, benefiting from global AI hype NoviqTech and Harvest Tech were best performers this month   The artificial intelligence (AI) theme has be...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

ASX hits record high, driven by consumer stocks Zip co-founder steps down, Collins Foods drops Invion doubles after commencing phase I/II trial    The ASX hit a new record on Tuesday, marking its third all-time high in just a week.  At th...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

ASX health stocks fall 2.15% in past five days, while broader market down 1.42%  MedAdvisor drops 30% on latest quarterly result as MicroX and Mach 7 also fall Micro X reports a ‘ho-hum’ results, while AGMs so far remain rather uneventful ...

Nyrada to launch phase I first-in-human trial after passing preclinical safety studies Neuren Pharmaceuticals ‘mini me’ Percheron seeks funds for rare disease program Another win for Pro Medicus, this time locally   Nyrada (ASX:NYR) share...

Despite the stunning advances in medical science – keyhole and robotic surgery and the like – the seemingly simpler challenges often remain unsolved. One of them is the ability to determine whether a stroke is the most common ischemic form...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

ASX health stocks rise 0.9% in past five days as broader markets lift 1.2%, despite Friday selloff ImpediMed’s latest quarterly result shows sales momentum building for Sozo device  Cold-cathode X-ray machine developer MicroX makes progres...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Micro-X embarking on ‘biggest advancement in X-ray since its invention’ in 1895 Its X-ray technology is smaller, lighter, more portable and faster than ever before Building its capability not just in medical sector but also security and de...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX tech sector falls 3.87% in April, but still outpaces broader markets YTD with a 19.55% rise Rich-lister Richard White increases his stake in ASX-listed music company Vinyl Group in April Video tech player Linius Technologies rises 33%...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

By Tim Boreham, Editor ASX code: ((HYD)) Market cap: $4.3m Shares on issue: 254,218,847 Financials (December half 2023): revenue $5.97m (down -17.5%), loss of $3.82m (-$1.96m deficit previously), cash of $847,277 (down -73.5%)* * After bala...

  Local markets get smashed, drop 1.8pc All 11 ASX sectors down Small Caps led by Task Group   A record close on Friday has found a typically ASX200-flavoured follow-up on Monday after the last session in New York saw US semiconductor dar...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((4DX)) - 4DMedical ((APM)) - APM Human Services International ((AMI)) - Aurelia Metals ((ACL)) - Australian Clinical Labs ((AVG)) - Australian Vintage ((AVD)) - Avada Gro...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

ASX medical devices to make inroads with FDA after a good year for drug developers FDA is reviewing Allegra’s Spinal Cage Device made from 3D-printed Sr-HT-Gahnite Stockhead reached out to Allegra’s board member, Dr Nick Hartnell   It’s b...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Quarterly earnings season is underway, and we’ve picked three highlights from the ASX Healthcare sector this morning.    Micro-X (ASX:MX1) Highlights: Strong improvement in Mobile DR sales and orders of $2.9m this quarter First payment rec...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

ASX health sector falls in line with broader markets as macroeconomic factors continue to create uncertainty Fitch Ratings Agency downgraded the credit rating of Ramsay Health Care (ASX:RHC) to BBB- from BBB Botanix Pharmaceuticals expects...

Innovative X-ray technology specialist Micro-X (ASX: MX1) has been awarded a significant $1.5 million contract with the Australian government for its unique Micro-X Rover systems. The new purchase order comes after the company decided to un...

Futures suggest the ASX will open slightly lower this morning as investors await the US Fed interest rates decision due this week. Back home, the Critical Minerals and Energy Investment Conference kicks off in Perth with representatives...

ASX to track Wall Street and open lower Instacart jumped by 12pc on Nasdaq IPO debut A look at how the world’s biggest companies have changed from 1980 to today   Australian shares are poised to track Wall Street and open lower on Wednesd...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((29M)) - 29Metals ((AIM)) - Ai-Media Technologies ((AMI)) - Aurelia Metals ((BXB)) - Brambles ((C79)) - Chrysos ((CYG)) - Coventry Group ((DDR)) - Dicker Data ((EML)) - E...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Medical devices offer faster route to commercialisation than drugs How newly listed Curvebeam AI aims to grab market share Stockhead reached out to Curvebeam AI CEO, Greg Brown   Despite the recent rally, the ASX Healthcare Index (XHJ) is...

Stroke has long been recognised as being among Australia’s most costly disease groups.  It occurs when a blood vessel supplying blood to the brain either suddenly becomes blocked or ruptures and begins to bleed which can result in part of t...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...